Unichem Laboratories (NSE:UNICHEMLAB) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)


NSE:UNICHEMLAB Unichem Laboratories Ltd NSE:UNICHEMLAB
65 GF Score
Price ₹474.55
GF Value ₹688.25
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Unichem Laboratories LT-Debt-to-Total-Asset?

Unichem Laboratories NSE:UNICHEMLAB +2.78% 65 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 65/100 and a GF Value™ of ₹688.25 (Significantly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Unichem Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Unichem Laboratories's long-term debt to total assets ratio declined from Mar. 2025 (0.02) to Mar. 2026 (0.02). It may suggest that Unichem Laboratories is progressively becoming less dependent on debt to grow their business.

Unichem Laboratories  (NSE:UNICHEMLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Unichem Laboratories LT-Debt-to-Total-Asset Related Terms

Unichem Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Unichem Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unichem Laboratories LT-Debt-to-Total-Asset Chart

Unichem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.02 0.02 0.02

Unichem Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 0.02 0.00 0.02
NSE:UNICHEMLAB
65GF Score
Unichem Laboratories Ltd NSE:UNICHEMLAB
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unichem Laboratories LT-Debt-to-Total-Asset Calculation

Unichem Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=651.2/37374.4
=0.02

Unichem Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=651.2/37374.4
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Unichem Laboratories (NSE:UNICHEMLAB) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Unichem Laboratories and its competitors.
Is Unichem Laboratories' LT-Debt-to-Total-Asset too high?
Unichem Laboratories' current LT-Debt-to-Total-Asset is 0.02. Overall, Unichem Laboratories has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Unichem Laboratories' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Unichem Laboratories and its competitors. Unichem Laboratories's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹688.25, compared to a current price of ₹474.55 — trading 31% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Unichem Laboratories' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued. The current stock price of ₹474.55 is trading 31% below its estimated GF Value™ of ₹688.25. GuruFocus considers Unichem Laboratories to be Significantly Undervalued.

Key valuation signals for NSE:UNICHEMLAB:

  • LT-Debt-to-Total-Asset: 0.02
  • GF Value™: ₹688.25 vs. price of ₹474.55 (31% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Unichem Laboratories Business Description

Other Exchanges 506690:India
Address Off. S. V. Road, Unichem Bhavan, Prabhat Estate, Jogeshwari (West), Mumbai, MH, IND, 400 102
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
65GF Score

Get the complete analysis for NSE:UNICHEMLAB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹474.55
Price
₹688.25
GF Value